BACKGROUND: Infection with human herpesvirus 8 (HHV-8) is common among men who have sex with men (MSM) in North America and Europe and is also found to be endemic in some regions of South America. Little is known about HHV-8 prevalence and its correlates among MSM in the Andean region. METHODS: We assessed HHV-8 seroprevalence among 497 MSM recruited for the 2002 Peruvian HIV sentinel surveillance program using a combined HHV-8 enzyme immunoassay and immunofluorescence assay algorithm. Logistic regression analysis was used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs) to determine the association between selected covariates and HHV-8 seropositivity. RESULTS: One hundred thirty-one (66.5%, 95% CI 63.1% to 69.9%) of 197 HIV-infected and 80 (26.7%, 95% CI 24.4% to 29.0%) of 300 HIV-uninfected MSM had serologic evidence of HHV-8 infection. Factors independently associated with HHV-8 infection were education<12 years (OR 1.7, 95% CI 1.1 to 2.7), anal receptive sex with the last partner (OR 2.0, 95% CI 1.2 to 3.3), self-reported sexually transmitted infection symptoms during the last year (OR 1.9, 95% CI 1.2 to 3.0), coinfection with HIV (OR 4.2, 95% CI 2.8 to 6.4) and chronic hepatitis B (OR 4.9, 95% CI 1.5 to 15.8). MSM with long-standing HIV infection were more likely to have serologic evidence of HHV-8 infection when compared with men with recently acquired HIV (OR 3.8, 95% CI 1.7 to 9.1). CONCLUSIONS: HHV-8 infection is common among both HIV-infected and HIV-negative MSM in Lima, Peru. HHV-8 seropositivity is correlated with anal receptive sex, self-reported sexually transmitted infection symptoms, and HIV infection among these MSM and thus seems to be sexually transmitted. HHV-8 infection seems to be acquired after HIV infection, suggesting that future studies should evaluate the mode of HHV-8 transmission and prevention strategies among HIV-uninfected MSM.
BACKGROUND:Infection with human herpesvirus 8 (HHV-8) is common among men who have sex with men (MSM) in North America and Europe and is also found to be endemic in some regions of South America. Little is known about HHV-8 prevalence and its correlates among MSM in the Andean region. METHODS: We assessed HHV-8 seroprevalence among 497 MSM recruited for the 2002 Peruvian HIV sentinel surveillance program using a combined HHV-8 enzyme immunoassay and immunofluorescence assay algorithm. Logistic regression analysis was used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs) to determine the association between selected covariates and HHV-8 seropositivity. RESULTS: One hundred thirty-one (66.5%, 95% CI 63.1% to 69.9%) of 197 HIV-infected and 80 (26.7%, 95% CI 24.4% to 29.0%) of 300 HIV-uninfected MSM had serologic evidence of HHV-8 infection. Factors independently associated with HHV-8 infection were education<12 years (OR 1.7, 95% CI 1.1 to 2.7), anal receptive sex with the last partner (OR 2.0, 95% CI 1.2 to 3.3), self-reported sexually transmitted infection symptoms during the last year (OR 1.9, 95% CI 1.2 to 3.0), coinfection with HIV (OR 4.2, 95% CI 2.8 to 6.4) and chronic hepatitis B (OR 4.9, 95% CI 1.5 to 15.8). MSM with long-standing HIV infection were more likely to have serologic evidence of HHV-8 infection when compared with men with recently acquired HIV (OR 3.8, 95% CI 1.7 to 9.1). CONCLUSIONS:HHV-8 infection is common among both HIV-infected and HIV-negative MSM in Lima, Peru. HHV-8 seropositivity is correlated with anal receptive sex, self-reported sexually transmitted infection symptoms, and HIV infection among these MSM and thus seems to be sexually transmitted. HHV-8 infection seems to be acquired after HIV infection, suggesting that future studies should evaluate the mode of HHV-8 transmission and prevention strategies among HIV-uninfected MSM.
Authors: Jorge Sanchez; Javier R Lama; Lourdes Kusunoki; Hugo Manrique; Pedro Goicochea; Aldo Lucchetti; Manuel Rouillon; Monica Pun; Luis Suarez; Silvia Montano; Jose L Sanchez; Stephen Tabet; James P Hughes; Connie Celum Journal: J Acquir Immune Defic Syndr Date: 2007-04-15 Impact factor: 3.731
Authors: A M G Cunha; A Caterino-de-Araujo; S C B Costa; E Santos-Fortuna; N C A Boa-Sorte; M S Gonçalves; F F Costa; B Galvão-Castro Journal: J Gen Virol Date: 2005-09 Impact factor: 3.891
Authors: Jeffrey T Parsons; Eric W Schrimshaw; Richard J Wolitski; Perry N Halkitis; David W Purcell; Colleen C Hoff; Cynthia A Gómez Journal: AIDS Date: 2005-04 Impact factor: 4.177
Authors: N H Dukers; N Renwick; M Prins; R B Geskus; T F Schulz; G J Weverling; R A Coutinho; J Goudsmit Journal: Am J Epidemiol Date: 2000-02-01 Impact factor: 4.897
Authors: V A U F Souza; L M Sumita; W Freire; H K Sato; J L Grandi; L C Pierrotti; M C Nascimento; C S Pannuti Journal: Braz J Med Biol Res Date: 2003-12-18 Impact factor: 2.590
Authors: Corey Casper; Mary Redman; Meei-Li Huang; John Pauk; Thomas M Lampinen; Stephen E Hawes; Cathy W Critchlow; Rhoda Ashley Morrow; Lawrence Corey; Nancy Kiviat; Anna Wald Journal: J Acquir Immune Defic Syndr Date: 2004-03-01 Impact factor: 3.731
Authors: R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch Journal: JAMA Date: 1998-07-01 Impact factor: 56.272
Authors: Lynnette K Tumwine; Rejani Lalitha; Claudio Agostinelli; Simon Luzige; Jackson Orem; Pier Paolo Piccaluga; Lawrence O Osuwat; Stefano A Pileri Journal: J Med Case Rep Date: 2011-02-14
Authors: Jessica L Castilho; Ahra Kim; Cathy A Jenkins; Beatriz Grinsztejn; Eduardo Gotuzzo; Valeria Fink; Denis Padgett; Pablo F Belaunzaran-Zamudio; Brenda Crabtree-Ramírez; Maria Mercedes Escuder; Rosa Alencar Souza; Simone B Tenore; Sidnei R Pimentel; Maria Letícia Rodrigues Ikeda; Paulo R de Alencastro; Unai Tupinanbas; Carlos Brites; Estela Luz; Juliana Netto; Claudia P Cortes; Alexandre Grangeiro; Bryan E Shepherd; Catherine C McGowan Journal: J Int AIDS Soc Date: 2021-01 Impact factor: 6.707